The article provides information on the results of "The Global Biotechnology Report 2006" compiled by Beyond Borders of Ernst & Young on venture capital investment in Europe as of May 2006. The venture capital investment raised by 20% to €1.4 billion in 2005. William Powlett Smith, leader ...
Reprints In this article A big biotech investment fund plowed more money into shares of two small companies as 2024 was coming to an end and the new year was just starting. Continue reading this article with a Barron’s subscription SUBSCRIBE NOWAerospace...
Of all the states angling to attract biotech firms, Bush's might have one of the most aggressive plans. His 2006-2007 budget proposal contains a number of biotech-friendly initiatives, such as the provision of 100 million for Florida universities to use to draw leading scientists to the state...
Bio-Europe 2007, to be held Nov. 12-14 in Hamburg, Germany, will present many of the most respected names in biotechnology to discuss key issues in the life sciences industry and the deals that drive it. The event is expected to be the largest stand-alone biotechnology event ever held, ...
As AstraZeneca looks to climb toward the top of biopharma companies by revenue by the end of the decade, smaller companies are looking to join the ranks of the unofficial Big Pharma club.
First, the French biotechannouncedit would be expanding its existing partnership with Japanese drugmaker Eisai. The initial collaboration was struck with Eisai in 2014 to jointly develop and commercialize an array of investigational Alzheimer’s disease treatments including aducanumab. ...
being based in europe, airbus has managed to have a more stable delivery curve. french unions are legendary for their strikes. but airbus has managed to weather this potential labor challenge better than boeing. boeing has had its share of strikes. boeing has also gone through periods of ...
the number where the four biggest firms have a market share above two-thirds has grown from 65 in 1997 to 97 by 2017. In Europe, where the data are less comprehensive, market power has been increasing for at least 20 years. Using data on western Europe’s largesteconomies—Britain, German...
Cancer research right now is not unlike the phase when whole-genome sequencing “took off,” says Thomas Knudsen, CEO of the bioinformatics firm CLC bio, which has customers in academia, biotech and pharma. First, the early adopters in large genome centers built their own tools, and then ...
9 "Up or out in oncology? Winning pathways for pharma and biotech in oncology," Bionest Partners, 2nd Edition, 2007. 10 Banerjee, S. & Barr, B., (2007) "Risk Rationale," Pharmaceutical Marketing Europe, pp.22-23 July/August 2007. 11 Ingate S., Tranter D., Banerjee A., Ho...